Nancy Bartlett, MD

Hematologic Oncologist, Medical Oncologist

Nancy Bartlett

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Clinical Expertise

  • Hematologic Malignancies

  • Lymphoma

Primary Academic Title

Professor of Medicine, Division of Oncology, Koman Chair in Medical Oncology, WashU Medicine

Board Certification

  • 1989: American Board of Internal Medicine, Internal Medicine
  • 1993: American Board of Internal Medicine, Medical Oncology
  • 2003: American Board of Internal Medicine, Medical Oncology

Training

  • 1986 - 1990: Intern and Resident, Internal Medicine, University of California, San Francisco, CA
  • 1990 - 1994: Postdoctoral Fellow, Medical Oncology, Stanford University, Stanford, CA

Education

  • 1986: MD, WashU Medicine, St. Louis, MO

Research & Select Publications

Research Interest

Clinical trials for patients with high risk or recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease

Research Publications

To B or not to B, that is the question: the role of bleomycin in early stage Hodgkin lymphoma
Authors:

Russler-Germain DA, Bartlett NL

Journal & Year:

Haematologica | 2026

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis
Authors:

Bartlett NL, Sehn LH, Assouline S, one or more additional authors omitted Budde LE

Journal & Year:

Am J Hematol | 2026

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Authors:

Diefenbach CS, Jegede O, Wang V, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Kahl BS

Journal & Year:

Blood | 2026

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma
Authors:

Abramson JS, Straus DJ, Bartlett NL, one or more additional authors omitted Lee HJ

Journal & Year:

Blood | 2026

New Standards in Advanced-stage Hodgkin Lymphoma: Selecting a Novel Regimen
Authors:

Cochran HC, Bartlett NL

Journal & Year:

Hematol Oncol Clin North Am | 2026

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Authors:

Zelenetz AD, Gordon LI, Abramson JS, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Sundar H

Journal & Year:

J Natl Compr Canc Netw | 2025

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Di…
Authors:

Andreadis C, Bobek O, Hsi ED, one or more additional authors omitted Bartlett NL

Journal & Year:

Leuk Lymphoma | 2025

Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Authors:

Rutherford SC, Li H, Herrera AF, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Evens AM

Journal & Year:

J Clin Oncol | 2025

ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia
Authors:

Davids MS, Kenderian SS, Flinn I, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Pinilla-Ibarz J

Journal & Year:

Blood | 2025

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up
Authors:

Domingo-Domènech E, Pro B, Illidge T, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Savage KJ

Journal & Year:

Blood Cancer J | 2025

DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features
Authors:

Thomas N, García-Prieto CA, Dreval K, one or more additional authors omitted Bartlett NL, one or more additional authors omitted Morin RD

Journal & Year:

Blood Cancer Discov | 2025

Bispecific antibodies in follicular lymphoma
Authors:

Nizamuddin IA, Bartlett NL

Journal & Year:

Haematologica | 2025

Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma
Authors:

Bartlett NL, Hahn U, Kim WS, one or more additional authors omitted Kim JA

Journal & Year:

Future Oncol | 2025

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Authors:

Bartlett NL, Hahn U, Kim WS, one or more additional authors omitted Kim JA

Journal & Year:

J Clin Oncol | 2025

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Authors:

Sehn LH, Bartlett NL, Matasar MJ, one or more additional authors omitted Budde LE

Journal & Year:

Blood | 2025